U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/590,435 Filing Date 08/23/2006 First Named Inventor FRASER, Paul Art Unit 1649 **Examiner Name** BALLARD, Kimberly

Attorney Docket Number 090931-380575

(Use as many sheets as necessary) Sheet 1

Substitute for form 1449/PTO

U. S. PATENT DOCUMENTS Examiner Cite **Document Number** Publication Date Name of Patentee or Pages, Columns, Lines, Where Initials* No. MM-DD-YYYY Applicant of Cited Document Relevant Passages or Relevant Figures Appear Number-Kind Code^{2 (ff known)} ^{US-} 6359112 03-19-2002 Kapurniotu et al. ^{US-} 6562836 05-13-2003 Szarek et al. ^{US-} 6610824 08-26-2003 Gaeta et al. ^{US-} 5686411 11-11-1997 Gaeta US-US-IIS-US-US-US-US-US-US-US-US-US-US-US-US-

		IGN PATENT DOCU			
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	WO-2002/24727	03-28-2002	Fraser		
	EP-0289287	01-28-1998	Cooper, G.J.S. et al.		
ļ				4	
					-
ļ					<u> </u>
	Cite No.1	Cite No.1 Country Code3 Number 4 Kind Code6 (# known) WO-2002/24727	Cite No.¹ Foreign Patent Document Publication Date MM-DD-YYYY Country Code³-Number⁴-Kind Code⁵ (if known) 03-28-2002	No.¹ Country Code³ Number⁴ Kind Code⁵ (if known) WO-2002/24727 Date MM-DD-YYYY Applicant of Cited Document of Cited	Cite No.¹ Country Code³¬Number⁴¬Kind Code⁵ (if known) Name of Patentee or Applicant of Cited Document Mhere Relevant Passages Or Relevant Figures Appear Name of Patentee or Applicant of Cited Document Mhere Relevant Passages Or Relevant Figures Appear

	- 100		
Examiner		Date	
Signature		Considered	
l		1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
		Application Number	10/590,435			
INF	ORMATIO	N DIS	CLOSURE	Filing Date	08/23/2006	
STA	ATEMENT	BY A	PPLICANT	T First Named Inventor FRASER, Paul		
<i>M</i>				Art Unit	1649	
(Use as many sheets as necessary)			lecessary)	Examiner Name	BALLARD, Kimberly	
Sheet	2	of	4	Attorney Docket Number	090931-380575	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title				
		International Search Report for PCT Patent Application No. PCT/CA2005/000247.			
		Opie, E.L., J. Exp. Med., 5:397-428, 1901.			
		Westermark and Grimelius, Acta Path. Microbiol Scand. sect. A., 81:291-300, 1973.			
-		de Koning et al., Diabetologia, 36:378-84, 1993.			
-		Lorenzo et al., Nature, 368:756-60, 1994.			
		Clark et al., Diabetes Res., 9:151-59, 1988.			
,		Johnson et al., N. Engl. J. Med., 321:513-18, 1989.			
		Moriarty and Raliegh, Biochemistry, 38:1811-818, 1999.			
		Betsholtz et al., FEBS Lett., 251:261-64, 1989.			
		Nilsson and Raleigh, J. Mol. Biol., 294:1375-385, 1999.			

	 	<u> </u>
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/590,435	
INF	ORMATION	DIS	CLOSURE	Filing Date	08/23/2006	
STA	STATEMENT BY APPLICANT			First Named Inventor	FRASER, Paul	
	(Use as many she	ate se n	arassani)	Art Unit	1649	
(ose as many should as necessary)			ecessaiy)	Examiner Name	BALLARD, Kimberly	
Sheet	3	of	4	Attorney Docket Number	090931-380575	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Higham et al., Eur. J. Biochem., 267:4998-5004, 2000.	
		Kayed et al., J. Mol. Biol., 287:81-796, 1999.	
		Hubbard et al., Biochem. J., 275:785-88, 1991.	
···		Saldanha and Mahadevan, Protein Eng., 4:539-44, 1991.	
		Higham et al., Febs Lett., 470:55-60, 2000.	
		Griffiths et al., Journal of the American Chemical Society, 117(12):3539-354, 1995.	
		Tsujimura et al., Transplantation, 74:1687-691, 2002.	
		Verchere et al., Proc. Natl. Acad. Sci. USA, 93:3492-496, 1996.	
		de Koning et al., Proc. Natl. Acad. Sci. USA, 91-8467-471, 1994	
		Sigurdsson, E.M. et al., In Vivo Reversal of Amyloid-ß Lesions in Rat Brain. J. Neuropath. Exp. Neurology. January, 2000. 59(1):11-17.	

Examiner	 Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number. Under the Panerwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449/PTO		Complete if Known			
		Application Number	10/590,435		
INFO	ORMATION	DIS	CLOSURE	Filing Date	08/23/2006
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	FRASER, Paul
(Use as many sheets as necessary)				Art Unit	1649
			ecessary)	Examiner Name	BALLARD, Kimberly
Sheet	4	of	4	Attorney Docket Number	090931-380575

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Kelly, J.W. The Environmental Dependency of Protein Folding Best Explains Prion and Amyloid Diseases. Proc. Natl. Acad. Sci. USA. February , 1998, 95:930-932.	
		Ghanta, J. et al., A Strategy for Designing Inhibitors of ß-Amyloid Toxicity. J. Biol. Chem. November 22, 1996. 271(47):29525-29528.	
		Aitken, J. et al., Suppression of Polycyclic Compounds of the Conversion of Human Amylin into Insoluble Amyloid. Biochem. J. June 18, 2003. 374:779-784.	
			

Signature Considered	Examiner	Date	
	Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.